Evidence map›Paper›PMID 41331870›Full record

ReviewCell communication and signaling : CCS2025

The interplay of estrogen, gut microbiome, and bone immunity in osteoporosis.

Maohua Chen, Jiaxu Wang, Yuanhang Yang, Yingge He, Liqi Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maohua Chen *Department of Pharmacy, Xinqiao Hospital, Army Medical University, Chongqing, 400037, China.
Jiaxu Wang *Department of Spinal Surgery, Ninth Medical Center, General Hospital of People's Liberation Army, Beijing, 100101, China.
Yuanhang Yang *School of Mechanical and Aerospace Engineering, Nanyang Technological University, Singapore, 639798, Singapore.
Yingge HeDepartment of Plastic and Cosmetic Surgery, Xinqiao Hospital, Army Medical University, Chongqing, 400037, China. 3545256390@tmmu.edu.cn.
Liqi LiDepartment of General Surgery, Xinqiao Hospital, Army Medical University, Chongqing, 400037, China. liliqi@tmmu.edu.cn.

Funding

Natural Science Foundation of Chongqing CSTB2023NSCQ-MSX0956Teaching Research Proiect of Army Medical University 2023B23Xingiao hospital Young DoctIncubation Program 2022YQB033
6 · The paper itself

Abstract

Osteoporosis is a global health concern arising from estrogen deficiency, intestinal dysbiosis, and dysregulation of the bone immune system. The absence of estrogen after menopause created environmental changes within the gut, where the microbial growth of the body was disturbed by the endocrine hormone, and inflammation increases due to the gut-bone axis, which leads to heightened bone loss. The gut microbiota, composed of bacteria and their metabolites such as short-chain fatty acids, play a crucial role in bone immune regulation by modulating immune cell function, influencing bone cell activity, and mediating epigenetic modifications. Malfunction of this system, characterized by the activation of immune cells and the imbalance of cytokines, also leads to the development of osteoporosis. Treatment strategies involved the regulation of the dysbiosis of the gut microbiota, reposition estrogen to the body, and immune modulation. The future direction should be the clarification of these interactions between estrogen and intestinal microflora, identification of new therapeutic targets, and personalization of osteoporosis management.

Indexed as

Bone and BonesEstrogensGastrointestinal MicrobiomeOsteoporosisAnimalsHumansEstrogensEstrogenGut microbiotaOsteoimmunityOsteoporosisTherapeutic strategies

Identifiers

PMID41331870
PMCPMC12673756

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.